In this week's Parallax podcast, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023.
Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London.
Drs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year’s most impactful trials:
• ORBITA-2 (AHA Scientific Sessions): PCI for stable angina
• FIRE (ESC Congress): Functional versus culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease
• DAPA-MI (AHA Scientific Sessions): SGLT2i in MI without diabetes or heart failure
• ILUMIEN IV (ESC Congress): OCT vs angiography-guided PCI
• OCTOBER (ESC Congress): OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions
• ARTESIA (ESC Congress): Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
• SELECT (AHA Scientific Sessions): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
What are the most impactful cardiovascular trials of 2023? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?
Catch the video version with slides by clicking here.
In this episode, Ankur and Danielle speak about the evidence in favour of a whole-food plant-based diet to improve cardiovascular health, the ACC prevention guidelines, how to talk to patients about positive dietary change, the issue of lack of nutrition training in cardiovascular fellowships and what Danielle’s diet looks like as a busy whole-food plant-based cardiology fellow. On her own podcast ‘Nutrition Rounds’ Danielle has discussions about evidence-based plant-based nutrition with physicians who are leading experts in nutrition and health.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.